184 related articles for article (PubMed ID: 34558098)
1. Translational and clinical pharmacology considerations in drug repurposing for X-linked adrenoleukodystrophy-A rare peroxisomal disorder.
Tieu JH; Sahasrabudhe SA; Orchard PJ; Cloyd JC; Kartha RV
Br J Clin Pharmacol; 2022 Jun; 88(6):2552-2563. PubMed ID: 34558098
[TBL] [Abstract][Full Text] [Related]
2. Drug repurposing in rare diseases: Myths and reality.
Fetro C; Scherman D
Therapie; 2020 Apr; 75(2):157-160. PubMed ID: 32241561
[TBL] [Abstract][Full Text] [Related]
3. [X-linked adrenoleukodystrophy and other peroxisomal diseases caused by a failing peroxisomal beta-oxidation system: clinical expression, diagnosis and treatment].
Wanders RJ; Barth PG; Schutgens RB; Van den Bosch H; Tager JM; Stroink H; Przyrembel H; Heymans HS
Tijdschr Kindergeneeskd; 1989 Oct; 57(5):186-97. PubMed ID: 2683204
[TBL] [Abstract][Full Text] [Related]
4. Reimagining old drugs with new tricks: Mechanisms, strategies and notable success stories in drug repurposing for neurological diseases.
Rani N; Kaushik A; Kardam S; Kag S; Raj VS; Ambasta RK; Kumar P
Prog Mol Biol Transl Sci; 2024; 205():23-70. PubMed ID: 38789181
[TBL] [Abstract][Full Text] [Related]
5. Therapy of X-linked adrenoleukodystrophy.
Semmler A; Köhler W; Jung HH; Weller M; Linnebank M
Expert Rev Neurother; 2008 Sep; 8(9):1367-79. PubMed ID: 18759549
[TBL] [Abstract][Full Text] [Related]
6. Novel Therapeutic Targets and Drug Candidates for Modifying Disease Progression in Adrenoleukodystrophy.
Pujol A
Endocr Dev; 2016; 30():147-60. PubMed ID: 26684655
[TBL] [Abstract][Full Text] [Related]
7. Harnessing Drug Repurposing for Exploration of New Diseases: An Insight to Strategies and Case Studies.
Jain P; Jain SK; Jain M
Curr Mol Med; 2021; 21(2):111-132. PubMed ID: 32560606
[TBL] [Abstract][Full Text] [Related]
8. Metformin-induced mitochondrial function and ABCD2 up-regulation in X-linked adrenoleukodystrophy involves AMP-activated protein kinase.
Singh J; Olle B; Suhail H; Felicella MM; Giri S
J Neurochem; 2016 Jul; 138(1):86-100. PubMed ID: 26849413
[TBL] [Abstract][Full Text] [Related]
9. [X-linked adrenoleukodystrophy].
Aubourg P
Ann Endocrinol (Paris); 2007 Dec; 68(6):403-11. PubMed ID: 17532287
[TBL] [Abstract][Full Text] [Related]
10. The effect of Lorenzo's oil on oxidative stress in X-linked adrenoleukodystrophy.
Deon M; Wajner M; Sirtori LR; Fitarelli D; Coelho DM; Sitta A; Barschak AG; Ferreira GC; Haeser A; Giugliani R; Vargas CR
J Neurol Sci; 2006 Sep; 247(2):157-64. PubMed ID: 16750542
[TBL] [Abstract][Full Text] [Related]
11. Drug repurposing for rare diseases.
Israr J; Alam S; Kumar A
Prog Mol Biol Transl Sci; 2024; 207():231-247. PubMed ID: 38942540
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of pharmacological induction of fatty acid beta-oxidation in X-linked adrenoleukodystrophy.
McGuinness MC; Zhang HP; Smith KD
Mol Genet Metab; 2001; 74(1-2):256-63. PubMed ID: 11592822
[TBL] [Abstract][Full Text] [Related]
13. Lovastatin therapy for X-linked adrenoleukodystrophy: clinical and biochemical observations on 12 patients.
Pai GS; Khan M; Barbosa E; Key LL; Craver JR; Curé JK; Betros R; Singh I
Mol Genet Metab; 2000 Apr; 69(4):312-22. PubMed ID: 10870849
[TBL] [Abstract][Full Text] [Related]
14. Elongation of very long-chain fatty acids is enhanced in X-linked adrenoleukodystrophy.
Kemp S; Valianpour F; Denis S; Ofman R; Sanders RJ; Mooyer P; Barth PG; Wanders RJ
Mol Genet Metab; 2005 Feb; 84(2):144-51. PubMed ID: 15670720
[TBL] [Abstract][Full Text] [Related]
15. Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease.
Shoaib M; Kamal MA; Rizvi SMD
Curr Drug Metab; 2017; 18(9):842-852. PubMed ID: 28595531
[TBL] [Abstract][Full Text] [Related]
16. Progression of X-linked adrenoleukodystrophy under interferon-beta therapy.
Korenke GC; Christen HJ; Kruse B; Hunneman DH; Hanefeld F
J Inherit Metab Dis; 1997 Mar; 20(1):59-66. PubMed ID: 9061569
[TBL] [Abstract][Full Text] [Related]
17. Drug Repurposing for Rare Diseases.
Roessler HI; Knoers NVAM; van Haelst MM; van Haaften G
Trends Pharmacol Sci; 2021 Apr; 42(4):255-267. PubMed ID: 33563480
[TBL] [Abstract][Full Text] [Related]
18. Adult-onset cerebello-brainstem dominant form of X-linked adrenoleukodystrophy presenting as multiple system atrophy: case report and literature review.
Ogaki K; Koga S; Aoki N; Lin W; Suzuki K; Ross OA; Dickson DW
Neuropathology; 2016 Feb; 36(1):64-76. PubMed ID: 26227820
[TBL] [Abstract][Full Text] [Related]
19. Repurposing old molecules for new indications: Defining pillars of success from lessons in the past.
Mittal N; Mittal R
Eur J Pharmacol; 2021 Dec; 912():174569. PubMed ID: 34653378
[TBL] [Abstract][Full Text] [Related]
20. Adrenoleukodystrophy-related protein can compensate functionally for adrenoleukodystrophy protein deficiency (X-ALD): implications for therapy.
Netik A; Forss-Petter S; Holzinger A; Molzer B; Unterrainer G; Berger J
Hum Mol Genet; 1999 May; 8(5):907-13. PubMed ID: 10196381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
